免疫检查点抑制剂在身体状况不佳的非小细胞肺癌中的临床疗效。
Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status.
机构信息
Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama 350-1298, Japan.
出版信息
Medicina (Kaunas). 2021 Nov 19;57(11):1273. doi: 10.3390/medicina57111273.
Abstract
Immune checkpoint inhibitors (ICIs) are standard treatments for patients with lung cancer. PD-1/PD-L1 or CTLA4 antibodies are chosen as the first-line therapy, contributing to the long-term survival and tolerability. Unlike molecular targeting agents, such as gefitinib, lung cancer patients with a poor performance status (PS) display unsatisfactory clinical improvements after ICI treatment. Several previous reports also demonstrated that the PS is identified as one of the most probable prognostic factors for predicting poor outcomes after ICI treatment. However, first-line pembrolizumab seemed to be effective for lung cancer patients with a PS of 2 if PD-L1 expression was greater than 50%. Currently, the induction of ICIs in patients with lung cancer with a poor PS is controversial. These problems are discussed in this review.
摘要
免疫检查点抑制剂（ICIs）是肺癌患者的标准治疗方法。PD-1/PD-L1 或 CTLA4 抗体被选为一线治疗药物，有助于长期生存和耐受性。与分子靶向药物（如吉非替尼）不同，免疫检查点抑制剂治疗后，身体状况较差（PS）的肺癌患者的临床改善并不令人满意。几项先前的报告还表明，PS 是预测免疫检查点抑制剂治疗后不良预后的最可能的预后因素之一。然而，如果 PD-L1 表达大于 50%，一线帕博利珠单抗似乎对 PS 为 2 的肺癌患者有效。目前，诱导身体状况较差的肺癌患者使用免疫检查点抑制剂存在争议。本文对这些问题进行了讨论。
相似文献
1
Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status.免疫检查点抑制剂在身体状况不佳的非小细胞肺癌中的临床疗效。
Medicina (Kaunas). 2021 Nov 19;57(11):1273. doi: 10.3390/medicina57111273.
2
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.在接受一线帕博利珠单抗治疗的晚期非小细胞肺癌患者中，基于2-脱氧-2-[18F]氟-D-葡萄糖正电子发射断层扫描-计算机断层扫描的基线总代谢肿瘤体积作为一种有前景的生物标志物。
Eur J Cancer. 2021 Jun;150:99-107. doi: 10.1016/j.ejca.2021.03.020. Epub 2021 Apr 20.
3
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
4
Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.免疫检查点抑制剂在体力状况不佳的非小细胞肺癌患者中的应用。
Cancer Sci. 2020 Oct;111(10):3739-3746. doi: 10.1111/cas.14590. Epub 2020 Aug 26.
5
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].[晚期非小细胞肺癌且PD-L1高表达患者对免疫检查点抑制剂单药治疗或联合化疗反应的评估]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02.
6
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.晚期非小细胞肺癌患者中抗 PD-1 和抗 PD-L1 抗体免疫检查点抑制剂再挑战时的给药切换：病例系列和文献复习。
Thorac Cancer. 2020 Jul;11(7):1927-1933. doi: 10.1111/1759-7714.13483. Epub 2020 May 18.
7
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.免疫检查点抑制剂在晚期非小细胞肺癌（NSCLC）患者中的疗效和安全性：一项系统文献综述。
Oncoimmunology. 2020 Jun 16;9(1):1774314. doi: 10.1080/2162402X.2020.1774314.
8
Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的非小细胞肺癌成人的体能状态和临终关怀。
Cancer. 2020 May 15;126(10):2288-2295. doi: 10.1002/cncr.32782. Epub 2020 Mar 6.
9
Lazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review.三例身体状况较差的局部晚期非小细胞肺癌患者对免疫治疗的拉撒路型反应：病例系列及文献综述
Ann Palliat Med. 2021 Jan;10(1):210-219. doi: 10.21037/apm-20-2279.
10
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.免疫检查点抑制剂与二线化疗治疗一线化疗耐药的肺癌患者。
Respir Med Res. 2020 Nov;78:100788. doi: 10.1016/j.resmer.2020.100788. Epub 2020 Aug 28.
引用本文的文献
1
Afatinib treatment of severe respiratory failure due to malignant lymphangitis in a dialysis patient with squamous cell carcinoma of the lung.阿法替尼治疗肺鳞癌透析患者恶性淋巴管炎所致严重呼吸衰竭
BMJ Case Rep. 2024 Feb 20;17(2):e253308. doi: 10.1136/bcr-2022-253308.
2
Safety and utility of Endoscopic Ultrasound with Bronchoscope-guided Fine Needle Aspiration (EUS-B-FNA) in suspected lung cancer patients with poor respiratory or general conditions: a prospective three-center observational study.经支气管镜超声引导下细针抽吸术（EUS-B-FNA）在呼吸或一般状况不佳的疑似肺癌患者中的安全性和实用性：一项前瞻性三中心观察研究。
BMC Pulm Med. 2023 Jun 14;23(1):206. doi: 10.1186/s12890-023-02508-2.
3
Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors.患有合并症且淋巴细胞计数低的住院癌症患者，使用免疫检查点抑制剂的临床结局较差。
Front Oncol. 2022 Sep 14;12:980181. doi: 10.3389/fonc.2022.980181. eCollection 2022.
4
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.阿替利珠单抗联合卡铂和依托泊苷作为小细胞肺癌一线化疗后的无进展生存期对总生存期有显著影响。
Thorac Cancer. 2022 Oct;13(19):2776-2785. doi: 10.1111/1759-7714.14621. Epub 2022 Sep 5.
本文引用的文献
1
Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population.体能状态对帕博利珠单抗一线单药治疗晚期非小细胞肺癌疗效的影响：真实世界人群的结果
Biology (Basel). 2021 Sep 9;10(9):890. doi: 10.3390/biology10090890.
2
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis.体能状态较差的非小细胞肺癌患者的一线免疫治疗：一项系统评价和荟萃分析。
Transl Lung Cancer Res. 2021 Jun;10(6):2917-2936. doi: 10.21037/tlcr-21-15.
3
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.PD-1/PD-L1 检查点抑制剂在生命晚期的应用：一项来自大型多中心队列的特设分析。
J Transl Med. 2021 Jun 24;19(1):270. doi: 10.1186/s12967-021-02937-9.
4
Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 - Systematic review and meta-analysis.免疫疗法在 ECOG PS 评分≥2 的 NSCLC 患者中的疗效和安全性 - 系统评价和荟萃分析。
Lung Cancer. 2021 Aug;158:97-106. doi: 10.1016/j.lungcan.2021.06.004. Epub 2021 Jun 6.
5
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.极低的体能状态是否会系统性地排除单药抗PD-1免疫治疗？一项对35例连续患者的多中心研究。
Cancers (Basel). 2021 Mar 2;13(5):1040. doi: 10.3390/cancers13051040.
6
Anti-PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status.抗程序性死亡蛋白 1（PD-1）单药治疗老年或体能状态较差的晚期非小细胞肺癌患者
Onco Targets Ther. 2021 Mar 17;14:1961-1968. doi: 10.2147/OTT.S301500. eCollection 2021.
7
Value of F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers.评估 F-FDG-PET 预测人类癌症中 PD-L1 表达和 PD-1 抑制治疗结果的价值。
Cancer Imaging. 2021 Jan 13;21(1):11. doi: 10.1186/s40644-021-00381-y.
8
Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%): A case series.帕博利珠单抗治疗体能状态差（≥3 分）和高 PD-L1 表达（TPS≥50%）的晚期 NSCLC 患者的临床结局：一项病例系列研究。
Thorac Cancer. 2020 Dec;11(12):3618-3621. doi: 10.1111/1759-7714.13713. Epub 2020 Oct 21.
9
Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy.合并症对接受抗 PD-1 免疫治疗的晚期非小细胞肺癌患者结局的影响。
Med Sci Monit. 2020 Sep 7;26:e922576. doi: 10.12659/MSM.922576.
10
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.一线帕博利珠单抗治疗 PD-L1 高表达（≥50%）且一般状况较差的非小细胞肺癌患者的结局。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-001007.
Zotero 插件